December 20, 2017
Novocure to Participate in 36th Annual J.P. Morgan Healthcare Conference
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will participate in the 36th Annual J.P. Morgan Healthcare Conference on January 10, 2018, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s… Read More
learn more
December 19, 2017
JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma
The EF-14 trial is the first trial in over a decade to demonstrate statistically and clinically significant extension of overall survival of patients with newly diagnosed glioblastoma regardless of patient characteristics ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the final analysis of its phase… Read More
learn more
December 18, 2017
Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer
PANOVA 3 will determine the efficacy and safety of Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine as a frontline treatment for unresectable locally advanced pancreatic cancer Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine more than doubled progression free survival and the one-year survival… Read More
learn more
December 1, 2017
Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma
Japan represents the largest medical device market in which Novocure has received governmental reimbursement for Optune for the treatment of newly diagnosed glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the Japanese Ministry of Health, Labour and Welfare has approved the recommendation by Japan’s Central… Read More
learn more
November 22, 2017
Novocure to Present at Two Upcoming Investor Conferences in December
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences in December. Asaf Danziger, Novocure’s Chief Executive Officer, and Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in a fireside chat at the Nasdaq 37th International Investor Conference on December… Read More
learn more
November 17, 2017
Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure’s EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Survival of 29.3 Percent
Increased compliance with Optune predicted survival in Novocure’s phase 3 pivotal EF-14 trial in newly diagnosed glioblastoma An Optune compliance threshold as low as 50 percent correlated with significantly improved outcomes in patients treated with Optune together with temozolomide versus patients treated with temozolomide alone… Read More
learn more
November 13, 2017
Novocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-Oncology
In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today 28 presentations on Tumor… Read More
learn more
November 9, 2017
Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology
Simulation research supports commitment to advance engineering of Tumor Treating Fields delivery systems In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure… Read More
learn more
November 8, 2017
Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology
An oral presentation will focus on the induction of autophagy by Tumor Treating Fields In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at… Read More
learn more
November 6, 2017
Novocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology
An oral presentation will focus on how compliance and treatment duration may predict survival in newly diagnosed glioblastoma patients treated with Optune® together with temozolomide In total, 54 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating… Read More
learn more